Market access teams should have more influence in clinical trial design, say Cutting Edge Information

By Natalie Morrison

- Last updated on GMT

Related tags: Clinical trial

Market access and clinical trial teams should work together: study
Health economics and outcomes research teams must have a greater influence over clinical trial design if pharma firms are to achieve reimbursement goals, according to Cutting Edge Information.

In a new study, analysts said brand profitability has dipped drastically in recent years because sponsors have tightened their belts in the harsher economic environment, resulting in more difficult and unpredictable market access.

The researchers say implementing health economics and outcomes research (HEOR) teams – which coordinate with the clinical group whilst the compound is in development – has been a popular choice when tackling the issue, as it provides the data to justify the price of a new product.

However, according to the study – which collected information from firms including Abbot, GlaxoSmithKline, and Pfizer – involving the endpoint teams early-on in trial design could mean even greater chances of seeing a healthy reimbursement.

The report, titled ‘Aligning Clinical and Commercial to Meet Payer Demands and Win Reimbursement’, said:  “Health economics teams’ primary responsibility is to develop information for payers, but companies that only analyse the completed clinical trial results to determine a product’s economic benefit face tough questions from payers.

“If the clinical trial does not collect the information needed to answer the payers questions, it might take more than additional analysis of existing data to gain payer support.”

By looking at information collected from a range of firms – from Big Pharma to small biotechs – the analysts found the most successful health economics groups have a say during trials.

Cutting Edge said that by working together, the business focussed commercial teams and the more academic medical staff who run clinical trials for the firms, could balance each other out, ensuring succinct, useful data.

 “The largest challenge is that teams located under medical affairs are more academic in nature, researching data for the data’s sake,”​ the analysts said. “Since the HEOR messages drive the overall market access strategy, not having commercially orientated messages can stunt the brand’s revenue stream.”

And though the authors admit the view could be seen as undermining the integrity of the medical team, they said it is in everyone’s interests to get the drug to market.

A director of health economics from an unnamed US biotech, which was involved in the study, added: “It doesn’t really matter where you sit because the whole discipline – like everything in the pharma world – is to sell drugs.”

Related news

Show more

Related products

show more

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us


View more